Innovation Pharmaceuticals Inc. - FORM 10-Q - EX-32.1 - SARBANES OXLEY CERTIFICATION 906 - February 22, 2011

Attached files

file filename
EX-10.32 - AMENDED & RESTATED LOAN DOCS - PUTNAM PARTNERS - Innovation Pharmaceuticals Inc.exh_10-32.htm
EX-10.34 - AMENDED & RESTATED LOAN DOCS-DAHLIA NORDLICHT - Innovation Pharmaceuticals Inc.exh_10-34.htm
EX-10.31 - GEORGE EVANS SETTLEMENT AGREEMENT - Innovation Pharmaceuticals Inc.exh_10-31.htm
EX-10.33 - AMENDED & RESTATED LOAN DOCS-WHITE STAR LLC - Innovation Pharmaceuticals Inc.exh_10-33.htm
10-Q - Innovation Pharmaceuticals Inc.form10q.htm
EX-31.1 - SARBANES OXLEY CERTIFICATION RULE 13A-14(A) - Innovation Pharmaceuticals Inc.exh_31-1.htm
Exhibit 32-1
 
CERTIFICATION PURSUANT TO
 
18 U.S.C. §1350, AS
 
ADOPTED PURSUANT TO
 
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 

 
I, Leo Ehrlich, Interim Chief Executive Officer and Chief Financial  Officer of Cellceutix Corporation, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002:
 

 
(1)  
the Quarterly Report on Form 10-Q of Cellceutix Corporation for the quarter ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
 
(2)  
 the information contained in the such Quarterly Report on Form 10-Q of Cellceutix Corporation for the quarter ended December 31, 2010 fairly presents, in all material respects, the financial condition and results of operations of Cellceutix Corporation
 

 
     
 
CELLCEUTIX CORPORATION
     
Date:  February 22, 2011
By:
/s/ Leo Ehrlich
 
Leo Ehrlich
 
Interim Chief Executive Officer, Chief Financial Officer,
 
Chairman of the Board of Directors
 
(Principal Executive, Accounting and Financial Officer)
 
     

 

 
 
 

Stock widget

Investing forum

Innovation Pharmaceuticals Inc. Reports